Group 1 - The core viewpoint of the news is that Fulongma's stock has shown significant growth this year, with a year-to-date increase of 163.13% and a market capitalization of 11.196 billion yuan [1] - As of November 26, Fulongma's stock price reached 26.95 yuan per share, with a trading volume of 850 million yuan and a turnover rate of 7.78% [1] - The company has seen a net inflow of main funds amounting to 5.2821 million yuan, with large orders contributing significantly to both buying and selling activities [1] Group 2 - Fulongma's main business involves the research, production, and sales of environmental sanitation equipment, with a revenue composition of 77.01% from environmental industry ecological operations and 20.70% from intelligent equipment [1][2] - As of September 30, the number of shareholders increased by 33.02% to 100,000, while the average circulating shares per person decreased by 24.82% [2] - For the period from January to September 2025, Fulongma reported a revenue of 3.599 billion yuan, a year-on-year decrease of 5.07%, and a net profit attributable to shareholders of 113 million yuan, down 1.83% year-on-year [2] Group 3 - Since its A-share listing, Fulongma has distributed a total of 933 million yuan in dividends, with 273 million yuan distributed over the past three years [3]

Core Viewpoint - The stock of Tibet City Investment has experienced fluctuations, with a recent decline of 2.00% and a total market capitalization of 12.73 yuan per share, reflecting a significant trading volume and changes in capital flow [1] Group 1: Stock Performance - As of November 26, Tibet City Investment's stock price has increased by 18.20% year-to-date, but has seen a decline of 8.02% over the last five trading days [1] - The stock has been on the龙虎榜 four times this year, with the most recent appearance on November 21, where it recorded a net buy of -41.46 million yuan [1] Group 2: Financial Performance - For the period from January to September 2025, Tibet City Investment reported a revenue of 837 million yuan, marking a year-on-year growth of 275.09%, while the net profit attributable to shareholders was -113 million yuan, reflecting a year-on-year increase of 24.53% [2] - The company has distributed a total of 176 million yuan in dividends since its A-share listing, with 32.15 million yuan distributed over the past three years [3] Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders for Tibet City Investment has increased by 10.30% to 61,200, with an average of 15,553 shares per shareholder, a decrease of 9.34% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI Real Estate ETF, with notable changes in their holdings compared to the previous period [3]

Core Viewpoint - Zhaojin Gold has shown significant stock performance with a year-to-date increase of 207.30%, despite a recent decline of 2.09% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Zhaojin Gold reported revenue of 340 million yuan, representing a year-on-year growth of 119.51%, and a net profit attributable to shareholders of 82.16 million yuan, up 191.20% year-on-year [2] Stock Market Activity - As of November 26, Zhaojin Gold's stock price was 12.20 yuan per share, with a trading volume of 110 million yuan and a turnover rate of 0.98%, leading to a total market capitalization of 11.33 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on October 13 [1] Shareholder Information - As of November 20, the number of shareholders for Zhaojin Gold was 62,000, a decrease of 8.82% from the previous period, while the average number of circulating shares per person increased by 9.68% to 14,977 shares [2] - The top ten circulating shareholders include new entrants such as GF Strategy Preferred Mixed Fund and Hong Kong Central Clearing Limited, holding 12.73 million shares and 12.47 million shares respectively [3]

Core Viewpoint - Shandong Steel's stock has shown fluctuations with a recent increase of 2.04%, while the company has experienced a decline in revenue but a significant increase in net profit year-on-year [1][2]. Group 1: Stock Performance - As of November 26, Shandong Steel's stock price is 1.50 CNY per share, with a market capitalization of 16.048 billion CNY [1]. - The stock has increased by 3.45% year-to-date, but has seen declines of 3.23% over the last five trading days, 6.83% over the last 20 days, and 4.46% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Shandong Steel reported operating revenue of 54.828 billion CNY, a decrease of 14.77% year-on-year [2]. - The company achieved a net profit attributable to shareholders of 140 million CNY, reflecting a year-on-year increase of 109.64% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders is 199,000, a decrease of 3.98% from the previous period [2]. - The average number of circulating shares per shareholder is 53,767, an increase of 4.14% [2]. - The company has distributed a total of 3.474 billion CNY in dividends since its A-share listing, with 321 million CNY distributed in the last three years [3]. Group 4: Major Shareholders - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 98.304 million shares, an increase of 58.581 million shares from the previous period [3]. - Guotai CSI Steel ETF is the fifth-largest circulating shareholder, holding 53.728 million shares as a new shareholder [3].

Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

Core Viewpoint - Wantong Development's stock has shown a significant increase of 58.26% year-to-date, despite recent declines in the short term [1][2] Group 1: Stock Performance - As of November 26, Wantong Development's stock price rose by 2.25% to 11.79 CNY per share, with a trading volume of 243 million CNY and a turnover rate of 1.12%, resulting in a total market capitalization of 22.288 billion CNY [1] - The stock has experienced a slight decline of 0.17% over the last five trading days, a 3.76% drop over the last 20 days, and a 13.69% decrease over the last 60 days [1] - The company has appeared on the trading leaderboard 16 times this year, with the most recent instance on September 4, where it recorded a net buy of -280 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Wantong Development reported a revenue of 317 million CNY, reflecting a year-on-year decrease of 4.37%, while the net profit attributable to shareholders was -19.8 million CNY, showing a significant increase of 82.94% compared to the previous year [2] - The company has cumulatively distributed 1.421 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Group 3: Shareholder Structure - As of September 30, 2025, Wantong Development had 132,100 shareholders, an increase of 124.95% from the previous period, with an average of 14,309 shares held per shareholder, down 56.16% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 24.6642 million shares, an increase of 13.0461 million shares, while Shenwan Hongyuan Securities Limited has reduced its holdings by 5.7777 million shares to 19.7186 million shares [3]

Core Viewpoint - Nocera Biopharma has seen a significant increase in stock price and trading activity, indicating positive market sentiment and potential growth in the biopharmaceutical sector [1][2]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and R&D services [2]. Stock Performance - The stock price of Nocera Biopharma has increased by 110.02% year-to-date, with a recent 6.66% rise over the last five trading days and a 12.28% increase over the last 20 days, although it has seen a 10.76% decline over the past 60 days [2]. - As of November 26, the stock was trading at 25.79 CNY per share, with a market capitalization of 45.51 billion CNY [1]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion CNY, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was a loss of 64.41 million CNY, an improvement of 76.61% compared to the previous period [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 16,500, with no change in the average number of circulating shares per person [3]. - Notable changes in institutional holdings include a decrease in shares held by some funds and the entry of new shareholders, indicating a shift in investor interest [3].

Core Viewpoint - The stock of Visionox Technology Co., Ltd. has shown fluctuations, with a recent increase of 2.02% to 9.11 CNY per share, while the company has experienced a year-to-date decline of 11.38% [1] Financial Performance - For the period from January to September 2025, Visionox reported a revenue of 6.051 billion CNY, reflecting a year-on-year growth of 3.50%. However, the net profit attributable to shareholders was -1.623 billion CNY, which is an increase of 9.67% compared to the previous year [2] Shareholder Information - As of November 20, 2025, the number of shareholders for Visionox increased to 71,700, marking a rise of 14.69%. The average circulating shares per person decreased by 12.81% to 19,444 shares [2] Dividend Distribution - Since its A-share listing, Visionox has distributed a total of 53.2384 million CNY in dividends, with no dividends paid in the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Visionox, holding 11.0486 million shares, which is an increase of 2.8175 million shares from the previous period [3]

Core Viewpoint - Shentong Express has shown a significant stock price increase of 43.28% year-to-date, despite recent fluctuations in trading performance [1][2]. Company Overview - Shentong Express Co., Ltd. is located in Qingpu District, Shanghai, and was established on November 1, 2001. It was listed on September 8, 2010. The company primarily engages in domestic express delivery, general freight, cargo transportation agency, warehousing services, and unloading services [1]. - The main revenue composition of the company is 98.67% from express services and 1.33% from other businesses [1]. Financial Performance - For the period from January to September 2025, Shentong Express achieved an operating income of 38.57 billion yuan, representing a year-on-year growth of 15.17%. The net profit attributable to the parent company was 756 million yuan, with a year-on-year increase of 15.81% [2]. - Since its A-share listing, the company has distributed a total of 1.614 billion yuan in dividends, with 131 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shentong Express was 40,700, a decrease of 4.36% from the previous period. The average circulating shares per person increased by 2.81% to 36,082 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the sixth largest, holding 31.0712 million shares, a decrease of 12.1407 million shares compared to the previous period [3].

Core Viewpoint - Hainengda's stock price has shown volatility, with a year-to-date decline of 14.00%, but a recent uptick of 4.00% over the last five trading days, indicating potential recovery signs in the market [1]. Group 1: Company Overview - Hainengda Communication Co., Ltd. is a leading provider of professional wireless communication equipment in China, established on May 11, 1993, and listed on May 27, 2011 [2]. - The company's main business includes the research, production, and sales of intercom terminals and cluster systems, contributing to 44.36% of revenue from terminals, 42.37% from systems, and 13.27% from OEM and others [2]. - As of September 30, 2025, Hainengda reported a revenue of 3.746 billion yuan, a year-on-year decrease of 10.26%, and a net profit attributable to shareholders of 186 million yuan, down 26.00% year-on-year [2]. Group 2: Market Performance - On November 25, Hainengda's stock rose by 2.09%, reaching 12.22 yuan per share, with a trading volume of 825 million yuan and a turnover rate of 5.36%, resulting in a total market capitalization of 22.224 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on June 13, where it recorded a net purchase of 324 million yuan [1]. Group 3: Shareholder Information - As of September 30, 2025, Hainengda had 257,200 shareholders, a decrease of 11.45% from the previous period, with an average of 4,987 circulating shares per shareholder, an increase of 12.94% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 13.6172 million shares, a decrease of 350,900 shares, and Southern CSI 1000 ETF, holding 9.9842 million shares, down by 94,300 shares [3].